Evidence map›Paper›PMID 40534846›Full record

ReviewFrontiers in immunology2025

Treatment strategies for rapid recurrence and progression after surgery for stage I pulmonary pleomorphic carcinoma: a case report and literature review.

Jing Zhang, Wenji Xiong, Hong Wang, Lemeng Sun, Chen Chen, Xueru Sun, Xiuyue Man, Lei Yang, Zhihong Li

Abstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jing ZhangDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Wenji XiongDepartment of Radiology, The First Hospital of Jilin University, Changchun, Jilin, China.
Hong WangDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Lemeng SunDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Chen ChenDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Xueru SunDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Xiuyue ManDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Lei YangDepartment of Cancer Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Zhihong LiDepartment of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary pleomorphic carcinoma (PPC) is a rare and poorly differentiated subtype of non-small cell lung cancer (NSCLC), primarily originating from non-epithelial tissue. Currently, there is no consensus on optimal treatment strategies for patients with PPC presenting diverse clinical features. This report describes an elderly male with stage I pulmonary pleomorphic carcinoma. Five months after surgery, the disease progressed rapidly, resulting in vertebral metastasis. Following a second surgery, the patient was treated with a programmed cell death protein-1 (PD-1) inhibitor combined with cytotoxic therapy. This regimen led to significant tumor shrinkage, achieving a partial response (PR). These findings suggest that combining immune checkpoint inhibitors (ICIs) with chemotherapy may improve outcomes for patients with advanced PPC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm Recurrence, LocalAgedDisease ProgressionHumansImmune Checkpoint InhibitorsMaleNeoplasm StagingTreatment OutcomeImmune Checkpoint Inhibitorsimmune checkpoint inhibitorsimmunotherapynon-small cell lung cancerpulmonary pleomorphic carcinomasintilimab

Identifiers

PMID40534846
PMCPMC12174158

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.